These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17351158)

  • 21. Influence of a pressure gradient distal to implanted bare-metal stent on in-stent restenosis after percutaneous coronary intervention.
    Jensen LO; Thayssen P; Thuesen L; Hansen HS; Lassen JF; Kelbaek H; Junker A; Hansen KN; Boetker HE; Krusell LR; Pedersen KE
    Circulation; 2007 Dec; 116(24):2802-8. PubMed ID: 18025527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The role of cytokines in restenosing coronary stents and the efficiency of its secondary prophylaxis with statins].
    Tepliakov AT; Rybal'chenko EV
    Klin Med (Mosk); 2008; 86(8):32-9. PubMed ID: 18819344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tetramethylpyrazine-eluting stents prevented in-stent restenosis in a porcine model.
    Ma G; Ding S; Feng Y; Shen C; Chen L; Chen Z
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):201-5. PubMed ID: 17703137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation.
    Zellweger MJ; Kaiser C; Brunner-La Rocca HP; Buser PT; Osswald S; Weiss P; Mueller-Brand J; Pfisterer ME;
    J Nucl Med; 2008 Apr; 49(4):550-6. PubMed ID: 18344439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is adjunctive balloon postdilatation necessary with drug-eluting stents? One center experience in Chinese patients.
    Gao Z; Yang YJ; Xu B; Chen JL; Qiao SB; Yao M; Chen J; Wu YJ; Liu HB; Dai J; Yuan JQ; Li JJ; Gao RL
    Chin Med J (Engl); 2008 Mar; 121(6):513-7. PubMed ID: 18364137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endoluminal phototherapy for prevention of restenosis: preliminary results at 6-month follow-up.
    Derkacz A; Protasiewicz M; Kipshidze N; Biały D; Poreba R; Bereś-Pawlik E; Abramski K; Mazurek A
    Photomed Laser Surg; 2005 Dec; 23(6):536-42. PubMed ID: 16356143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of sirolimus-eluting stent on calcified coronary lesions.
    Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2008 Jan; 121(1):6-11. PubMed ID: 18208656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
    Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
    Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions.
    Li JJ; Qin XW; Yang XC; Li ZC; Zeng HS; Xu B; Gao Z; Wu YJ; Zhang X; Zhang CY
    Clin Chim Acta; 2008 Oct; 396(1-2):38-42. PubMed ID: 18634770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of statin medications on perioperative and long-term outcomes following carotid endarterectomy or stenting.
    Perler BA
    Semin Vasc Surg; 2007 Dec; 20(4):252-8. PubMed ID: 18082842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy).
    Weisz G; Moses JW; Teirstein PS; Holmes DR; Raizner AE; Satler LF; Mishkel G; Wilensky RL; Wang P; Kuntz RE; Popma JJ; Leon MB
    Am J Cardiol; 2007 Apr; 99(8):1044-50. PubMed ID: 17437725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
    Glueck CJ; Rawal B; Khan NA; Yeramaneni S; Goldenberg N; Wang P
    Metabolism; 2009 Feb; 58(2):233-8. PubMed ID: 19154957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention.
    Roy P; Buch AN; Javaid A; Okabe T; Raya V; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Gevorkian N; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Feb; 101(3):293-9. PubMed ID: 18237587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers.
    Yasue H; Mizuno Y; Harada E; Itoh T; Nakagawa H; Nakayama M; Ogawa H; Tayama S; Honda T; Hokimoto S; Ohshima S; Hokamura Y; Kugiyama K; Horie M; Yoshimura M; Harada M; Uemura S; Saito Y;
    J Am Coll Cardiol; 2008 May; 51(18):1742-8. PubMed ID: 18452779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
    J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of statin therapy on restenosis after coronary stent implantation.
    Walter DH; Schächinger V; Elsner M; Mach S; Auch-Schwelk W; Zeiher AM
    Am J Cardiol; 2000 Apr; 85(8):962-8. PubMed ID: 10760335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.